Click here to read Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection, the full clinical study published in Oct 2023
The Challenge: CIED Infection Rising
The incidence of infection following implantation of cardiac implantable electronic devices (CIEDs) is increasing at a faster rate than that of device implantation.
Between 1993 and 2008, there was a 96% increase in the implantation of CIEDs. This coincided with a 210% increase in CIED infections.1
22-56% 2,3 of patients are considered to be at increased risk for CIED infection.
Preventing CIED Infections
TauroPace™ is a simple and effective way to reduce the risk of CIED infections. 4.
It is used to irrigate the surgical site, generator and leads..
It is clinically proven that:.
The active ingredient within TauroPace™ is Taurolidine, which kills more than 500 types of bacteria and fungi 7 (including MRSA and VRE). Taurolidine is not an antibiotic and therefore avoids antibiotic resistance concerns. It quickly degrades to taurine, cardon dioxide and water when it enters the body.
- TauroPace™ reduces acute CIED infection risk in patients by up to 100%. 4
- TauroPace™ enhances wound healing. 5
- NO antibiotics, NO resistance. 6
Proven Results
A study published in October 2023 8 demonstrates that TauroPace™ is effective in preventing CIED infections:These findings confirm the antimicrobial efficacy of taurolidine, the main active ingredient of TauroPace™: It kills a broad range of bacteria and fungi (incl. MRSA and VRSA), without generating bacterial resistance.
- Between 2017 and 2022, more than 1,300 patients undergoing at least one invasive CIED procedure were included.
- TauroPace™ was used during 654 procedures on 631 patients.
- 3% hydrogen peroxide (H2O2) was used during 551 procedures on 532 patients.
- The acute CIED infection rate was 0.0% after adjunct TauroPace™ use and 1.09% after adjunct H2O2 use (over a 3-month period).
- After total follow-up (15 months), CIED infection rate was 0.46% with TauroPace™ vs. 1.63% with H2O2.
TauroPace™ H2O2 p-value Number of Procedures 654 551 Number of Infections 0 6 Infection Rate 0.00% 1.09% <0.0075
Preventing CIED Infections Webinar Series:
Dr. Benito Baldauf MD, Consultant Cardiologist
1. Greenspon, A.J., et al., 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol, 2011. 58(10): p. 1001-6.
2. Mittal S et al. (2014) Heart Rhythm 11(4):595-601.
3. Eby E et al (2018) EP Europace. (s1):i106
4. Henke J, et al. (2022) European Journal of Arrhythmia & Electrophysiology.2022;8.
5. Wu L et al. (2021) Ann Transl Med. 2021;9;1010.
6. Radakovic S, et al. (2020) Antibiotics.2020;9:166
7. Torres-Viera, C., et al. (2000) Activities of Taurolidine In Vitro and in Experimental Enterococcal Endocarditis. Antimicrobial Agents and Chemotherapy. 44 (6): 1720–1724.
8. Borov et al. Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection. EP Europace 2023. DOI: 10.1093/europace/euad306